Over 80 million people in the US and over 1 billion people worldwide suffer with respiratory challenges such as COPD (chronic obstructive pulmonary disease), CHF (congestive heart failure), and asthma. These patients require special breathing monitoring, training, and therapeutic devices in the hospital and at home. The Alvio device can serve as an enabler to lower costs and improve patient outcomes across the continuum of care in the hospital and at home.
“It is exciting to see the Alvio approaching commercialization,” stated Bez Arkush, founder and President of QOL. “We have already had significant interest from many major medical institutions, healthcare professionals and international distributors for the Alvio, so it is great to see it now taking shape. I am pleased to be working with ADMT which has the development, regulatory expertise and experience to bring this breakthrough technology to market.” ADMT is the exclusive manufacturer of Alvio technology.
QOL and ADMT plan to first introduce the non-regulated version of Alvio for sale to the public for breathing training, while preparing submission to FDA for clearance of Alvio for medical applications in the US market and for CE marking for Europe and Canadian CMDCAS.
“We believe the Alvio platform is positioned to disrupt the $5+ billion US and the $6+ billion international respiratory therapy markets. Alvio is the world’s only fully integrated respiratory therapy platform, mobile connected, respiratory sensor and trainer that can redefine respiratory therapy and training markets,” continued Mr. Arkush.
“Alvio can provide an end-to-end solution for lung function testing, respiratory training, and data tracking, utilizing an interactive connection among patients, their caregivers, health care providers, and payers. Alvio employs games and activities to incentivize patients, especially children, to complete respiratory therapy, overcoming chronic non-compliance issues. The Alvio platform can solve a major challenge in the healthcare market by offering the next generation of a combination of data and device connectivity – it’s Respiratory Therapy 2.0™.”
Andre’ DiMino, President and CEO of ADMT stated, “The upcoming release of Alvio is the first of our new line of digital medical device technologies in our development pipeline. We believe the success of any one of our new proprietary medical device technologies could be a gamechanger for the company with the potential to become the standard of care for the medical applications they address.”